Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Challenges Remain Amid Advances in RCC and Prostate Cancer

April 5th 2019

David I. Quinn, PhD, MBBS, discusses the molecular diagnosis of renal cell carcinoma and also highlights emerging therapies in the treatment of patients with different subtypes of prostate cancer.

Dr. Armstrong Discusses Findings of ARCHES Trial in Prostate Cancer

April 2nd 2019

Andrew J. Armstrong, MD, associate professor of medicine and surgery, Department of Medicine, Duke University School of Medicine, Duke Cancer Institute, discusses findings from the ARCHES trial in patients with metastatic hormone-sensitive prostate cancer.

Higano Examines Emerging Role of PARP Inhibitors in mCRPC

April 2nd 2019

Celestia Higano, MD, FACP, discusses the potential for PARP inhibitors in patients with metastatic castration-resistant prostate cancer, as well as the role of darolutamide in nonmetastatic disease.

Dr. Gartrell on Tolerability of SM-88 in Prostate Cancer

April 1st 2019

Benjamin A. Gartrell, MD, assistant professor of urology, Albert Einstein College of Medicine, medical oncologist, Montefiore Medical Center, discusses the tolerability of SM-88 in the treatment of patients with prostate cancer.

Strategies Take Shape for a New Disease State in Prostate Cancer

April 1st 2019

Now that the FDA has carved out nonmetastatic, castration-resistant prostate cancer as a new disease state, the decision about whether to administer recently approved antiandrogen therapies in this setting hinges on the rate of increase in prostate-specific antigen levels and comorbidities.

Future Directions in Renal Cell Carcinoma Management

March 29th 2019

Further Exploring TKI/I-O Combination Regimens in mRCC

March 29th 2019

mRCC: When is TKI/I-O Combination Therapy Appropriate?

March 29th 2019

Novel Combinations in mRCC: Axi/Pembro vs Axi/Avelumab

March 29th 2019

Goals in Previously Treated Advanced Renal Cell Carcinoma

March 29th 2019

Selecting an Optimal Second-Line Regimen for mRCC

March 29th 2019

Frontline Therapy for mRCC: Sequencing and Goals

March 29th 2019

Evaluating I-O Monotherapy's Value in Treating mRCC

March 29th 2019

mRCC: Identifying and Managing AEs in TKIs and IO Therapy

March 29th 2019

Role of TKIs in Intermediate or Poor-Risk mRCC

March 29th 2019

Favorable-Risk mRCC: Choosing Appropriate Frontline Therapy

March 29th 2019

Risk Stratification in Metastatic Renal Cell Carcinoma

March 29th 2019

Dr. Tagawa Discusses Darolutamide in CRPC

March 28th 2019

Scott T. Tagawa, MD, Richard A. Stratton Associate Professor in Hematology and Oncology, associate professor of clinical medicine and urology at Weill Cornell Medicine, associate attending physician, NewYork-Presbyterian-Weill Cornell Medical Center, discusses darolutamide in castration-resistant prostate cancer.

Dr. Higano on Role of PARP Inhibitors in Prostate Cancer

March 26th 2019

Celestia Higano, MD, FACP, member, Clinical Research Division, Fred Hutchinson Cancer Research Center, professor, Department of Medicine and Urology, University of Washington, Seattle Cancer Care Alliance, discusses the role of PARP inhibitors in prostate cancer.

ADT and the Need for a Multidisciplinary Approach

March 25th 2019